Skip to Main Content

Advertisement

Skip Nav Destination

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Blood Adv (2023) 7 (9): 1929–1943.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement